Method of treating cancer using selective estrogen receptor modulators
Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
1. A method of treating an estrogen receptor positive breast cancer in a subject, wherein the estrogen receptor positive breast cancer is resistant to one or more aromatase inhibitors, the method comprising administering to a subject a compound, (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino}-4-methoxyphenyll-5,6,7,8-tetrahydronaphthalen-2-ol, which has the structure
2. The method of claim 1 , wherein the compound is administered as part of a pharmaceutical composition.
3. The method of claim 2 , wherein the composition is administered daily as a single dose.
4. The method of claim 2 , wherein the composition is administered daily as a multi-dose.
5. The method of claim 1 , wherein the one or more aromatase inhibitor(s) is selected from the group consisting of anastrozole, letrozole, exemestane, formestane, fadrozole, aminoglutethimide, testolactone, and combinations thereof.
6. The method of claim 5 , wherein the one or more aromatase inhibitor(s) is selected from anastrozole, letrozole, exemestane, and combinations thereof.
7. The method of claim 1 , wherein an effective amount of the compound is administered.
8. The method of claim 7 , wherein the effective amount is from about 200 mg/day to about 500 mg/day.
9. The method of claim 8 , wherein the effective amount is about 400 mg/day.
10. The method of claim 7 , wherein the compound is administered by oral administration, intravenous administration, intradermal injection, intramuscular injection or subcutaneous injection.
11. The method of claim 10 , wherein the compound is administered by oral administration.
12. The method of claim 1 , further comprising administering an effective amount of at least one compound selected from the group consisting of a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6 inhibitor), an antiestrogen, a ligand of retinoic acid or retinoxic X receptor, an antiprogestin, an antiandrogen, vitamin D or metabolite thereof, a farnesyl transferase inhibitor, a PPARa or gamma agonist and a MAP kinase inhibitor.
13. The method of claim 12 , wherein the at least one compound is a CDK4/6 inhibitor.
14. The method of claim 12 , wherein the at least one compound is an antiestrogen.